Study of Ruxolitinib in Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether ruxolitinib added to capecitabine is
effective in improving the overall survival of patients with metastatic pancreatic cancer.